However, Aharoni et al. detected that EAE induced by myelin proteolipid protein (PLP) immunization compared to myelin oligodendrocyte glycoprotein (MOG)35-55 displayed lower NfL levels at the same time point of clinical progression [176], suggesting that different myelin peptides induce variable neurodegenerative change, potentially making it difficult to set NfL limits for different MS histopathologically characterized lesions. Here, PLP1 is linked to myeloid sarcoma.